Lanzamiento Enero 2027

Ensayo controlado aleatorizado2020Vínculos de autores con la industriaAcceso abierto

CYP1A2 genotype and acute effects of caffeine on resistance exercise, jumping, and sprinting performance

Grgic J, Pickering C, Bishop DJ, Schoenfeld BJ, Mikulic P, Pedisic Z

Journal of the International Society of Sports Nutrition · 43 citas

Etiquetas de revisión

Vínculos de autores con la industria

Datos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.

Cómo se estudió

Diseño
Ensayo controlado aleatorizado (indexado por PubMed)
Estudiado en
Personas
Resultado principal
Marcadores de salud y funcionamiento

Quién lo pagó

Financiación
Financiación independiente
Autores
Al menos un autor declara un vínculo económico con la industria

Según la declaración de financiación del texto completo.

Publicación

Publicado
2020-01-03 · J Int Soc Sports Nutr · vol. 17 · número 1 · pág. 21
Editorial
Springer Science+Business Media
Citado
58 citas · más que el 96% de estudios similares · 4.6× el promedio de su campo
Impacto
Entre el 10 % más citado de su campo
Referencias
42 trabajos
Acceso
Acceso abierto (revista) · CC-BY
Áreas de investigación
Coffee research and impacts · Muscle metabolism and nutrition · Genetics and Physical Performance
Palabras clave
Bench press, Caffeine, Medicine, Wingate test, Jumping, Sprint, Ingestion, Placebo, Animal science, Internal medicine, Resistance training, Physical therapy, Anaerobic exercise, Physiology, Biology
MeSH
humans, caffeine, cytochrome p-450 cyp1a2, cross-over studies, double-blind method, genotype, adult, male, athletic performance, resistance training, young adult, performance-enhancing substances, sports nutritional physiological phenomena

6 autores

  • Jozo Grgić🇦🇺 · autor de correspondenciaVictoria University
  • Craig Pickering🇬🇧University of Lancashire
  • David John Bishop🇦🇺Edith Cowan University; Victoria University
  • Brad Jon Schoenfeld🇺🇸Lehman College
  • Pavle Mikulić🇭🇷University of Zagreb
  • Željko Pedišić🇦🇺Victoria University

Resumen

El texto original del estudio, en el idioma en que se publicó.

Background

It has been suggested that polymorphisms within CYP1A2 impact inter-individual variation in the response to caffeine. The purpose of this study was to explore the acute effects of caffeine on resistance exercise, jumping, and sprinting performance in a sample of resistance-trained men, and to examine the influence of genetic variation of CYP1A2 (rs762551) on the individual variation in responses to caffeine ingestion.

Methods

Twenty-two men were included as participants (AA homozygotes n = 13; C-allele carriers n = 9) and were tested after the ingestion of caffeine (3 mg/kg of body mass) and a placebo. Exercise performance was assessed with the following outcomes: (a) movement velocity and power output in the bench press exercise with loads of 25, 50, 75, and 90% of one-repetition maximum (1RM); (b) quality and quantity of performed repetitions in the bench press exercise performed to muscular failure with 85% 1RM; (c) vertical jump height in a countermovement jump test; and (d) power output in a Wingate test.

Results

Compared to placebo, caffeine ingestion enhanced: (a) movement velocity and power output across all loads (effect size [ES]: 0.20-0.61; p < 0.05 for all); (b) the quality and quantity of performed repetitions with 85% of 1RM (ES: 0.27-0.85; p < 0.001 for all); (c) vertical jump height (ES: 0.15; p = 0.017); and (d) power output in the Wingate test (ES: 0.33-0.44; p < 0.05 for all). We did not find a significant genotype × caffeine interaction effect (p-values ranged from 0.094 to 0.994) in any of the analyzed performance outcomes.

Conclusions

Resistance-trained men may experience acute improvements in resistance exercise, jumping, and sprinting performance following the ingestion of caffeine. The comparisons of the effects of caffeine on exercise performance between individuals with the AA genotype and AC/CC genotypes found no significant differences.

Trial registration

Australian New Zealand Clinical Trials Registry. ID: ACTRN12619000885190.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.